BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 33238261)

  • 21. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
    Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
    Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.
    Kebriaei P; Saliba R; Rondon G; Chiattone A; Luthra R; Anderlini P; Andersson B; Shpall E; Popat U; Jones R; Worth L; Ravandi F; Thomas D; O'Brien S; Kantarjian H; de Lima M; Giralt S; Champlin R
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):584-92. PubMed ID: 21867666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
    Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
    J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Jabbour E; Kantarjian HM; Aldoss I; Montesinos P; Leonard JT; Gómez-Almaguer D; Baer MR; Gambacorti-Passerini C; McCloskey J; Minami Y; Papayannidis C; Rocha V; Rousselot P; Vachhani P; Wang ES; Wang B; Hennessy M; Vorog A; Patel N; Yeh T; Ribera JM
    JAMA; 2024 Jun; 331(21):1814-1823. PubMed ID: 38722621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
    Chen H; Xu LP; Zhang XH; Wang Y; Chen YH; Yan CH; Cheng YF; Han W; Chen Y; Qin YZ; Liu Y; Chang YJ; Liu KY; Huang XJ
    Leuk Res; 2022 Oct; 121():106930. PubMed ID: 36007342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.
    Shi T; Wang H; Xie M; Li X; Zhu L; Ye X
    Clinics (Sao Paulo); 2020; 75():e2011. PubMed ID: 33206758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).
    Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Peng Y; Huang J; Yin J; Meng F; Cao Y; Huang L; Li D; Zhang Y; Zhang D; Meng L; Han Z; Hong Z
    Expert Rev Hematol; 2024; 17(4-5):173-180. PubMed ID: 38616308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.
    Aubert L; Petit A; Bertrand Y; Ray-Lunven AF; Angoso M; Pluchart C; Millot F; Saultier P; Cheikh N; Pellier I; Plantaz D; Sirvent A; Thouvenin-Doublet S; Valduga J; Plat G; Rialland F; Henry C; Esvan M; Gandemer V
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29441. PubMed ID: 34854546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
    Shahzad M; Hussain A; Tariq E; Anwar I; Faisal MS; Syed L; Karam A; Chaudhary SG; Ahmed N; Bansal R; Khurana S; Singh AK; Byrd KP; Hematti P; Abhyankar SH; McGuirk JP; Mushtaq MU
    Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):178-187. PubMed ID: 36682989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.
    Radich J; Gehly G; Lee A; Avery R; Bryant E; Edmands S; Gooley T; Kessler P; Kirk J; Ladne P; Thomas ED; Appelbaum FR
    Blood; 1997 Apr; 89(7):2602-9. PubMed ID: 9116308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
    Short NJ; Kantarjian H; Kanagal-Shamanna R; Sasaki K; Ravandi F; Cortes J; Konopleva M; Issa GC; Kornblau SM; Garcia-Manero G; Garris R; Higgins J; Pratt G; Williams LN; Valentine CC; Rivera VM; Pritchard J; Salk JJ; Radich J; Jabbour E
    Blood Cancer J; 2020 May; 10(5):61. PubMed ID: 32457305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
    Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].
    Cai W; Liu B; Xu Y; Chen S; Sun A; He J; Shen H; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):105-9. PubMed ID: 27014978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.